Osborne Clarke has advised the shareholders of LYKON, provider of home biomarker tests, on the sale to the nutrition app Lifesum.
The digital health company LYKON, founded in Berlin in 2018, aims to empower people to take their health into their own hands. To this end, the company is active in the field of personalised nutrition and personalised medicine and offers a wide range of DNA and blood tests for home use. A few drops of blood or saliva are enough to provide users with customised nutrition and action recommendations to help them achieve their health goals.
Lifesum, founded in Stockholm in 2013, is the world's leading nutrition app and now operates in 36 markets worldwide. Personalised insights enable millions of users to make smarter choices about their diet and develop sustainable habits.
Following the sale, Lifesum and LYKON aim to jointly revolutionise Europe's wellbeing market with personalised health solutions.
“Biomarkers provide real answers beyond just examining weight and offer a deeper perspective on the state of wellness and progression. Combining biomarkers with innovative technology enables personalized supplements and coaching to truly empower people to take care of their health. Joining forces with Lifesum allows us to provide consumers with unparalleled insights to their health. Our shared vision to improve health and well-being through a personalized approach makes it possible to leverage our offerings at scale,” says Tobias Teuber, founder of LYKON.
The Osborne Clarke team advising the shareholders of LYKON, led by Maximilian Vocke, consisted of Mikael Nelson, Dana Alpar, Joanna Chudzinski and Benedikt Hülsmann (all Corporate / M&A) and Ann-Kristin Lochmann (Tax).
Corporate communications and press contacts
Connect with one of our experts
